Amicus Therapeutics (NASDAQ:FOLD) Sets New 12-Month Low – Should You Sell?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $7.97 and last traded at $8.09, with a volume of 400639 shares trading hands. The stock had previously closed at $8.43.

Analyst Ratings Changes

FOLD has been the topic of a number of research analyst reports. Wells Fargo & Company dropped their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Price Performance

The stock has a market capitalization of $2.44 billion, a price-to-earnings ratio of -44.17, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The company’s 50 day moving average is $9.22 and its 200 day moving average is $9.91.

Institutional Trading of Amicus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Virtus Fund Advisers LLC purchased a new position in shares of Amicus Therapeutics during the fourth quarter worth about $29,000. Covestor Ltd boosted its stake in shares of Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 2,312 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Amicus Therapeutics in the third quarter valued at $55,000. GF Fund Management CO. LTD. purchased a new position in Amicus Therapeutics during the 4th quarter valued at about $59,000. Finally, R Squared Ltd purchased a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $79,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.